Lite Strategy (LITS) Cash & Equivalents (2010 - 2026)
Lite Strategy (LITS) posted quarterly Cash & Equivalents of $7.5 million for Q1 2026, down 63.2% year-over-year from $20.5 million in Q1 2025, and down 13.86% quarter-over-quarter from $8.8 million in Q4 2025.
Lite Strategy (LITS) Cash & Equivalents (2010 - 2026) Analysis & Trends
Lite Strategy's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $7.5 million for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 63.2% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $7.5 million (down 63.2% YoY), while the FY2025 annual figure was $18.0 million, up 386.13% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $7.5 million, down from $8.8 million in the prior quarter.
- The five-year high for Cash & Equivalents was $169.0 million in Q1 2022, with the low at $2.4 million in Q1 2024.
- The 5-year median for Cash & Equivalents is $10.1 million (2025), against an average of $27.0 million.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents soared 1634.65% in 2022, then sank 95.83% in 2023.
- Lite Strategy's Cash & Equivalents stood at $124.2 million in 2022, then tumbled by 95.83% to $5.2 million in 2023, then soared by 358.06% to $23.7 million in 2024, then sank by 63.05% to $8.8 million in 2025, then retreated by 13.86% to $7.5 million in 2026.
- Business Quant data shows LITS's Cash & Equivalents at $7.5 million in Q1 2026, $8.8 million in Q4 2025, and $10.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | 7.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.54 Mn |
| Dec 31, 2025 | 8.76 Mn |
| Sep 30, 2025 | 10.11 Mn |
| Jun 30, 2025 | 18.01 Mn |
| Mar 31, 2025 | 20.50 Mn |
| Dec 31, 2024 | 23.70 Mn |
| Sep 30, 2024 | 6.95 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Mar 31, 2024 | 2.37 Mn |
| Dec 31, 2023 | 5.17 Mn |
| Sep 30, 2023 | 3.37 Mn |
| Jun 30, 2023 | 16.91 Mn |
| Mar 31, 2023 | 8.81 Mn |
| Dec 31, 2022 | 124.17 Mn |
| Sep 30, 2022 | 14.65 Mn |
| Jun 30, 2022 | 15.74 Mn |
| Mar 31, 2022 | 169.04 Mn |
| Dec 31, 2021 | 12.55 Mn |
| Sep 30, 2021 | 145.50 Mn |
| Jun 30, 2021 | 8.54 Mn |